Date:4/30/2012

al services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.PAREXEL International Corporation Consolidated Condensed Statement of OperationsUnauditedThree Months EndedThree Months Ended(in thousands, except per share data)March 31, 2012March 31, 2011As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
355,992$
-$ 355,992$
301,396$
-$ 301,396Reimbursement revenue56,03756,03751,56551,565  Total revenue412,029-412,029352,961-352,961Costs and expenses:
Direct costs241,445241,445195,605

(a)

(368)

(b)

195,237
Reimbursable out-of-pocket expenses56,03756,03751,56551,565
Selling, general and administrative 67,15967,15967,700

(a)

(7)

(b)

67,693
Depreciation15,16615,16613,58213,582
Amortization2,1982,1982,5002,500
Restructuring charge 1,807(1,807)

(c)

-144(144)

(d)'/>"/>

SOURCE PAREXEL International Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. PAREXEL Announces Date of Third Quarter Fiscal Year 2012 Earnings Release and Conference Call
3. PAREXEL to Address New Regulatory Guidelines and Data Standards at DIA EuroMeeting
4. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
5. PAREXEL International to Present at Barclays Capital Healthcare Conference
6. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
7. PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
8. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
9. PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
10. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
11. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology